The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2021 | Optimizing transplantation outcomes for patients with AML
Andreas Burchert, MD, University of Marburg, Marburg, Germany, outlines the latest data on the optimization of transplantation outcomes for patients with acute myeloid leukemia. Dr Burchert describes how the risk of relapse currently presents the greatest challenge in the field and comments on the need to improve the rate and depth of remissions prior to transplantation. In the post-transplant setting, Dr Burchert highlights the need to have highly tolerable therapeutic options available. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.
